brenbto
Posted - 4 days ago
$TARS
ElmerFuddz
Posted - 4 days ago
$TARS bullish 1. Improved Liquidity and Financial Flexibility: By securing $200 million in financing and choosing to draw $75 million initially, Tarsus Pharmaceuticals gains immediate liquidity. The availability of additional capital in tranches provides flexibility to fund ongoing operations or growth initiatives as needed, which can be crucial for a pharmaceutical company facing the high costs of research, development, and potential commercialization of products. 2. Refinancing Existing Debt: The fact that part of the initial draw is used to repay an existing credit facility suggests that this new financing may have more favorable terms, such as potentially lower interest rates or more suitable repayment conditions. This can reduce financial strain and improve the company’s debt profile.
DonCorleone77
Posted - 4 days ago
$TARS Tarsus Pharmaceuticals refinances existing debt with $200M financing Tarsus Pharmaceuticals announced that it has secured $200 million in committed capital from funds associated with Pharmakon Advisors, LP. Tarsus has elected to draw $75 million on the closing date, April 19, 2024, with the remaining $125 million of committed capital available at the company's option in three tranches through specified time windows, the last ending in December 2025. Net proceeds to the Company at closing will be approximately $40 million following the repayment of the existing credit facility, as well as fees and expenses associated with the transaction. The new five-year interest-only credit facility with Pharmakon provides for three potential additional loan tranches, to be drawn at the Company's option, in principal amounts up to $25 million, $50 million and $50 million, respectively, the latter two tranches available upon achievement of certain revenue thresholds. The credit facility bears interest at a floating rate based upon the secured overnight financing rate, plus a margin of 6.75% per annum. SOFR is subject to a 3.75% floor. Interest on the funded loan is paid quarterly in arrears until April 19, 2029, the Maturity Date, with the unpaid principal amount of the outstanding loan due and payable on the Maturity Date. There is no warrant coverage to the lenders and no financial covenants associated with the financing. Pharmakon Advisors, LP is a leading investor in non-dilutive debt for the life sciences industry and is the investment manager of the BioPharma Credit funds. Established in 2009, funds managed by Pharmakon Advisors, LP have committed $7.8 billion across 51 investments. Armentum Partners served as Tarsus' financial advisor on this transaction.
TheTradeXchange
Posted - 4 days ago
$TARS Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
Stock_Titan
Posted - 4 days ago
$TARS Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
https://www.stocktitan.net/news/TARS/tarsus-strengthens-financial-position-and-refinances-existing-debt-uk443yp0j4ak.html
Night_Owl_Biotech
Posted - 1 week ago
Attached (left) = all acquisitions of comm'l-stage non-oncology biopharmas acquired since 1/1/17. It's our non-professional experience most new therapies are acquired within 1 to 2 years post approval. We do not recall many acquisitions of comm'l-stage bios w/approvals post 3 years (pls lets us know if we are missing any). (Right) = all non-oncology bios with a FDA approval over the last 4 years (market cap $100MM+). If we had to guess (for entertainment), we suspect $VALN would be acquired sooner rather than later since Pfizer already owns a good piece of VALN & VALN's new vaccine should be a good fit. VALN cash includes $103MM from the sale of PRV. Takeda sells Vonoprazan in Japan making $PHAT an obvious candidate. $TARS is 1 of the best performers in biopharma the last 12 months (excl. recent financing). Next step is a B/O (a guess). Last, watch $URGN as Friday's trading was highly unusual. B/O candidate? This is not investment advice. Be careful, our data may be wrong too.
shared_alerts
Posted - 2 weeks ago
-04/12/2024-
📉 SCANNER UPDATE📈 $EYPT $OMER $TARS $SAVA ↩️
Blazed_Beast
Posted - 2 weeks ago
$TARS
Doozio
Posted - 2 weeks ago
$TARS maybe sum moar chop chop bahhhht 🧠⏰ is…..
bobmoney
Posted - 03/30/24
$TARS impressive run...under the radar...
TheMonz
Posted - 03/28/24
$TARS Let’s roll!
Ayedyn
Posted - 1 month ago
@Mattedbumhair Tarsus $TARS because they have the potential to be the only prophylactic for tick and bug-transmitted diseases like lyme in humans.
insiderbuyingselling
Posted - 1 month ago
$TARS new insider selling: 4436 shares. http://insiderbuyingselling.com/?t=TARS
glimdbea
Posted - 1 month ago
$MDGL I wish I could be thrilled like many are. I am happy, but more relieved than happy. If things continue as expected this will be my 2nd best gain ever. PRVB was #1. I think Madrigal will make a lot of money for years to come. Treating a serious disease with a head start of several years with no competition. I will ride this one for at least 2-3 years. Another bio I plan to hold long term is $TARS They have a treatment already approved for dry eyes. Not very sexy, but dry eyes is a common problem and current treatments are not adequate. Long term I also have $CRSP I plan to never sell Crispr. For diversity I also hold a bunch of Vanguard and Fidelity funds which I will also hold forever. How about you?
Raket1
Posted - 1 month ago
ElmerFuddz
Posted - 1 month ago
$TARS Still waiting…my precious.
Ayedyn
Posted - 1 month ago
@Idvst8 check tarsus $TARS out.
Duker1976
Posted - 1 month ago
$TARS listened to the first investor conference...I got distracted by a work call a couple of times but one the the guys, think the CEO ...said sales going exceeding well and hitting targets sooner than anticipated...paraphrasing that ...need to go back and listen for exact quote...also said at some point this year they may hire an additional 60 or so sales persons.
ElmerFuddz
Posted - 1 month ago
$TARS This is below the offering price!!!
Duker1976
Posted - 1 month ago
$TARS mm just trying to scrape as many stop loss shares as possible for institutions in my opinion
ElmerFuddz
Posted - 1 month ago
$TARS Waiting with dry powder!
Biotech_Beast
Posted - 1 month ago
$TARS up over 100% the past few months. Xdemvy launch has a very strong first full quarter. $XBI $IBB https://seekingalpha.com/article/4676825-tarsus-pharmaceuticals-stock-q4-2023-earnings-strong-launch-buy
IN0V8
Posted - 1 month ago
$TARS Jefferies raises target price to $44 from $30
ElmerFuddz
Posted - 1 month ago
$SPY Buy $TARS, get rich. They’re going to kill the tick-bite market, while continuing on the amazing eye care run that just started last quarter. And for my pharma reps, we all know that scripts are down first quarter of the year, deductibles haven’t been met yet.
Stock_Titan
Posted - 1 month ago
$TARS Tarsus to Participate at Upcoming Investor Conferences
https://www.stocktitan.net/news/TARS/tarsus-to-participate-at-upcoming-investor-7iadx1b74n5e.html
Stock_Titan
Posted - 1 month ago
$TARS Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis
https://www.stocktitan.net/news/TARS/tarsus-introduces-mite-party-campaign-for-xdemvy-r-lotilaner-t1oaold44ljl.html
Ayedyn
Posted - 1 month ago
@dyrn for me, $TARS after this
Ayedyn
Posted - 1 month ago
$TARS PT of $600 in 5-6 years.
